| import nltk | |
| nltk.download(['stopwords', 'punkt']) | |
| from summarize import summarize | |
| from data import data | |
| import streamlit as st | |
| st.write(""" | |
| # Pharma Company POC | |
| """) | |
| st.sidebar.image("./NarrativaLogoBlanco.png") | |
| def make_summarizing(new_body, hide=False, num_sentences=3): | |
| if hide: | |
| return '' | |
| result = summarize( | |
| new_body, sentence_count=num_sentences, language='english') | |
| return result | |
| st.subheader("Overview") | |
| st.write(""" | |
| ##### Topics: | |
| - Cancer | |
| - immuno-oncology | |
| - New Therapy | |
| - BiTE | |
| """) | |
| st.write(""" | |
| ##### Summary: | |
| """) | |
| st.write(make_summarizing(data["intro"])) | |
| st.write('---') | |
| st.write('##### Conversation:') | |
| st.write(""" | |
| ***Overview of the current therapeutic landscape for cancer and the immuno-oncology*** | |
| """) | |
| st.write(make_summarizing(data["block_1"])) | |
| st.write(""" | |
| ***How does the BiTE platform and constituent BiTE molecules actually work*** | |
| """) | |
| st.write(make_summarizing(data["block_2"], num_sentences=4)) | |
| st.write(""" | |
| ***Where BiTE molecules are currently being studied*** | |
| """) | |
| st.write(make_summarizing(data["block_3"], num_sentences=3)) | |
| st.write(""" | |
| ***Practial approach: Myeloma and BiTE*** | |
| """) | |
| st.write(make_summarizing(data["block_4"], num_sentences=6)) | |
| st.write(""" | |
| ***Acute Myeloid Leukemia and BiTE molecules*** | |
| """) | |
| st.write(make_summarizing(data["block_5"], num_sentences=6)) | |
| st.write(""" | |
| ***BiTE molecules for solid tumor types*** | |
| """) | |
| st.write(make_summarizing(data["block_6"], num_sentences=4)) | |
| st.write(""" | |
| ***Takeaways*** | |
| """) | |
| st.write(make_summarizing(data["block_7"], num_sentences=3)) | |
| st.write(""" | |
| # MRD Slide Deck | |
| """) | |
| st.write(""" | |
| ### Current Landscape in Minimal Residual Disease (MRD) Testing in Hematologic Malignancies | |
| """) | |
| st.write(""" | |
| - MRD is the presence of malignant cells under the detection limit of conventional methods | |
| - Strong prognostic indicator of patient outcomes | |
| - Potential for use in guiding treatment decisions | |
| - Intensity of therapy | |
| - Appropriateness of SCT | |
| - Currently measured using flow cytometry or qPCR | |
| - Newer testing methods are emerging | |
| - MRD is currently being evaluated as a potential surrogate endpoint, and may have the potential to replace or augment morphological CR as a response criteria in certain hematologic malignancies | |
| """) | |